Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doxorubicin Hydrochloride

FDA-approved product (injectable, injection), marketed as Adriamycin Pfs, Doxil (Liposomal), Doxorubicin Hydrochloride and 2 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Doxorubicin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute myelomonocytic leukemia
  • Bone sarcoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Carcinoma
  • Childhood epithelioid sarcoma
  • Classic Hodgkin lymphoma
  • Epithelioid sarcoma
  • Heart failure
  • HER2 Positive Breast Carcinoma
  • Hodgkins lymphoma
  • Kaposi's sarcoma
  • Malignant epithelial tumor of ovary
  • Multiple myeloma
  • and 9 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anthracyclines and related substances
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 0 of 1 lab record
Open Doxorubicin Hydrochloride in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doxorubicin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

    NCT03264131 · start 2018-10-11

    Registered record
    Registry ID
    NCT03264131
    Conditions
    Lymphoma; Adult T-Cell Leukemia/Lymphoma; Lymphatic Diseases
    Interventions
    Brentuximab Vedotin; CHEP
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-10-11
    Completion
    2025-12-15
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Adult T-Cell Leukemia/Lymphoma; Lymphatic Diseases
    InterventionBrentuximab Vedotin; CHEP
    PhasePhase 2
    Registry statusCompleted

  • Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer

    NCT03632798 · start 2018-08-01

    Registered record
    Registry ID
    NCT03632798
    Conditions
    Recurrent Ovarian Cancer
    Interventions
    ChemoID assay; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2018-08-01
    Completion
    2019-06-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Ovarian Cancer
    InterventionChemoID assay; Chemotherapy
    PhasePhase 3
    Registry statusWithdrawn

  • Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

    NCT03023124 · start 2018-03-04

    Registered record
    Registry ID
    NCT03023124
    Conditions
    Solitary Fibrous Tumors
    Interventions
    Trabectedin; Adriamycin; Dacarbazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-03-04
    Completion
    2024-12-06
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolitary Fibrous Tumors
    InterventionTrabectedin; Adriamycin; Dacarbazine
    PhasePhase 2
    Registry statusCompleted

  • Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

    NCT02876302 · start 2018-01-24

    Registered record
    Registry ID
    NCT02876302
    Conditions
    Inflammatory Breast Cancer (IBC)
    Interventions
    Ruxolitinib; Paclitaxel; Doxorubicin; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-01-24
    Completion
    2024-10-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammatory Breast Cancer (IBC)
    InterventionRuxolitinib; Paclitaxel; Doxorubicin; Cyclophosphamide
    PhasePhase 2
    Registry statusCompleted

  • Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients

    NCT03318835 · start 2017-08-22

    Registered record
    Registry ID
    NCT03318835
    Conditions
    Thalidomide
    Interventions
    Thalidomide combined with R-CHOP; R-CHOP
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-08-22
    Completion
    2020-08-22
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThalidomide
    InterventionThalidomide combined with R-CHOP; R-CHOP
    PhasePhase 3
    Registry statusUnknown

  • Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer

    NCT03164993 · start 2017-06-01

    Registered record
    Registry ID
    NCT03164993
    Conditions
    Cancer, Breast; Triple Negative Breast Cancer
    Interventions
    Atezolizumab; Pegylated liposomal doxorubicin; Cyclophosphamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-06-01
    Completion
    2023-09-30
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer, Breast; Triple Negative Breast Cancer
    InterventionAtezolizumab; Pegylated liposomal doxorubicin; Cyclophosphamide; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma

    NCT03023878 · start 2017-03-13

    Registered record
    Registry ID
    NCT03023878
    Conditions
    High-risk Diffuse Large B-Cell Lymphoma
    Interventions
    Blinatumomab; Investigator's Choice Chemotherapy; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-03-13
    Completion
    2019-10-28
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh-risk Diffuse Large B-Cell Lymphoma
    InterventionBlinatumomab; Investigator's Choice Chemotherapy; Dexamethasone
    PhasePhase 2
    Registry statusCompleted

  • Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

    NCT02871869 · start 2016-09

    Registered record
    Registry ID
    NCT02871869
    Conditions
    Diffuse, Large B-Cell, Lymphoma
    Interventions
    vindesine; cyclophosphamide; Epirubicin; prednisone tablets; Cinobufacini Tablets; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2016-09
    Completion
    2021-12
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse, Large B-Cell, Lymphoma
    Interventionvindesine; cyclophosphamide; Epirubicin; prednisone tablets +2 more
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

    NCT02797717 · start 2015-11

    Registered record
    Registry ID
    NCT02797717
    Conditions
    Classical Hodgkins Lymphoma in Children and Adolescents.
    Interventions
    Radiotherapy:; Vincristine; Etoposide; Prednisone; Doxorubicin; Dacarbazine; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2015-11
    Completion
    2027-12
    Enrolment
    2,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClassical Hodgkins Lymphoma in Children and Adolescents.
    InterventionRadiotherapy:; Vincristine; Etoposide; Prednisone +3 more
    PhaseNot applicable
    Registry statusRecruiting

  • PDD vs PAD to Treat Initially Diagnosed MM

    NCT02577783 · start 2015-10

    Registered record
    Registry ID
    NCT02577783
    Conditions
    Multiple Myeloma
    Interventions
    PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone; PAD regimen: bortizomib, dexamethasone and doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-10
    Completion
    2021-12
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionPDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone; PAD regimen: bortizomib, dexamethasone and doxorubicin
    PhasePhase 4
    Registry statusUnknown

  • Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

    NCT02356159 · start 2015-09-24

    Registered record
    Registry ID
    NCT02356159
    Conditions
    Myelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia; Multiple Myeloma
    Interventions
    Rituximab; Conditioning chemotherapy; TMS; FLAG; EPOCH-F; Hematopoietic stem cell transplant; Palifermin; Acetaminophen; Diphenhydramine; Prednisone; Epinephrine; IV Saline; ECG; ECHO; MUGA; DEXA; CT chest; PET; MRI; BM aspirate; BM biopsy; Lumbar puncture
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-09-24
    Completion
    2025-03-25
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia +1 more
    InterventionRituximab; Conditioning chemotherapy; TMS; FLAG +18 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.

    NCT02506777 · start 2015-07

    Registered record
    Registry ID
    NCT02506777
    Conditions
    Breast Cancer
    Interventions
    metformin; Fluoruracil; Doxorubicin; Cyclophosphamide; melatonin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-07
    Completion
    2020-08
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionmetformin; Fluoruracil; Doxorubicin; Cyclophosphamide +1 more
    PhasePhase 2
    Registry statusUnknown

  • PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS

    NCT03268772 · start 2015-04-01

    Registered record
    Registry ID
    NCT03268772
    Conditions
    Soft Tissue Sarcoma
    Interventions
    PLD and IFO
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-04-01
    Completion
    2020-12-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft Tissue Sarcoma
    InterventionPLD and IFO
    PhasePhase 2
    Registry statusUnknown

  • CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma

    NCT02336386 · start 2014-12

    Registered record
    Registry ID
    NCT02336386
    Conditions
    Extramedullary Plasmacytoma
    Interventions
    CDD; CDD Plus Bortezomib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-12
    Completion
    2016-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtramedullary Plasmacytoma
    InterventionCDD; CDD Plus Bortezomib
    PhasePhase 3
    Registry statusUnknown

  • A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

    NCT02522234 · start 2014-02-25

    Registered record
    Registry ID
    NCT02522234
    Conditions
    Neutropenia
    Interventions
    F-627 240 μg/kg; F-627 320 μg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-02-25
    Completion
    2015-08-19
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeutropenia
    InterventionF-627 240 μg/kg; F-627 320 μg/kg
    PhasePhase 1 / Phase 2
    Registry statusCompleted